var data={"title":"Voriconazole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Voriconazole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7163?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=voriconazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Voriconazole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Voriconazole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234784\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vfend;</li>\n      <li>Vfend IV</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855140\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Voriconazole;</li>\n      <li>Sandoz-Voriconazole;</li>\n      <li>Teva-Voriconazole;</li>\n      <li>VFEND;</li>\n      <li>VFEND For Injection;</li>\n      <li>Voriconazole For Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234822\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Azole Derivative;</li>\n      <li>\n        Antifungal Agent, Oral;</li>\n      <li>\n        Antifungal Agent, Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234787\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, invasive, including disseminated and extrapulmonary infection; treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 6 mg/kg every 12 hours for 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: 4 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> <b>Note:</b> If patient has inadequate clinical response, titrate in 50 mg/dose increments for weight &lt;40 kg and 100 mg/dose increments for weight &ge;40 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight &lt;40 kg: 100 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight &ge;40 kg: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate recommendations:</i> Oral: 200 to 300 mg every 12 hours <b>or </b>weight-based dosing (3 to 4 mg/kg) every 12 hours. <b>Note:</b> In patients able to tolerate oral administration, may consider oral in place of IV; however, IV administration is recommended in seriously ill patients (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration of therapy: Minimum of 6 to 12 weeks, although duration is highly dependent on degree/duration of immunosuppression, disease site, and evidence of disease improvement (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, invasive (prophylaxis during prolonged neutropenia) (alternative therapy) (off-label use): </b>Oral: 200 mg twice daily (IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, ocular (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endophthalmitis:</i> Intravitreal: 100 mcg/0.1 mL of an extemporaneously prepared solution administered intravitreally (need for a repeat dose is at physician discretion); concomitant systemic (IV or oral) voriconazole therapy is also recommended (Hariprasad 2008; Hoenigl 2013; Kramer 2006; IDSA [Patterson 2016]; Riddell 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Keratitis:</i> Ophthalmic: Dosing may vary; the following dosing regimen has been used in trials: 1 drop of an extemporaneously prepared 1% ophthalmic solution applied topically to the cornea of the affected eye every 1 hour while awake for 1 week, then every 2 hours while awake for 2 weeks; further continuation was at physician discretion (IDSA [Patterson 2016]; Prajna 2010; Prajna 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidemia in non-neutropenic patients and disseminated </b> <b><i>Candida</i></b> <b>infections in skin, and infections in abdomen, kidney, bladder wall and wounds: </b> Treatment should continue for a minimum of 14 days following resolution of symptoms or following last positive culture, whichever is longer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 6 mg/kg every 12 hours for 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: 3 to 4 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling: </i>Maintenance dose: <b>Note:</b> If patient has inadequate clinical response, titrate in 50 mg/dose increments for weight &lt;40 kg and 100 mg/dose increments for weight &ge;40 kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight &lt;40 kg: 100 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight &ge;40 kg: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate recommendations (IDSA [Pappas 2016]):</i> Candidemia in non-neutropenic patients:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial therapy: 400 mg (6 mg/kg) IV every 12 hours for 2 doses, followed by 200 mg (3 mg/kg) IV or orally every 12 hours. <b>Note: </b>Voriconazole is considered alternative therapy and offers little advantage over fluconazole as first-line therapy of candidemia.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Step-down therapy (after patient has responded to initial therapy): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Isolates of <span class=\"organism\">C. glabrata</span> (voriconazole-susceptible isolates): 200 to 300 mg (3 to 4 mg/kg) twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Isolates of <span class=\"organism\">C. krusei</span> (selected cases): 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration: Continue for 14 days <b>after</b> first negative blood culture and resolution of signs/symptoms; step-down therapy to voriconazole (eg, after 5 to 7 days in nonneutropenic patients) is recommended only in select clinically stable patients with certain voriconazole-susceptible isolates and negative repeat cultures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, endophthalmitis (with or without vitritis) (off-label use) (IDSA [Pappas 2016]):</b> Voriconazole-susceptible isolates:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic therapy: </i>Loading dose: 400 mg (6 mg/kg) IV twice daily for 2 doses, then 300 mg (4 mg/kg) IV or orally twice daily for at least 4 to 6 weeks until examination indicates resolution; for patients with vitritis or with macular involvement (with or without vitritis), an intravitreal injection of voriconazole or amphotericin B deoxycholate is also recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intravitreal therapy: </i>Patients with vitritis or with macular involvement (with or without vitritis): Intravitreal: 100 mcg of an extemporaneously prepared solution in 0.1 mL sterile water or NS; concomitant antifungal systemic therapy is also recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, esophageal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling: </i> Oral: Treatment should continue for a minimum of 14 days, and for at least 7 days following resolution of symptoms. <b>Note:</b> If patient has inadequate clinical response, titrate in 50 mg/dose increments for weight &lt;40 kg and 100 mg/dose increments for weight &ge;40 kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight &lt;40 kg: 100 mg every 12 hours; maximum: 300 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight &ge;40 kg: 200 mg every 12 hours; maximum: 600 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fluconazole-refractory: Oral, IV (off-label route): 200 mg (3 mg/kg) twice daily for 14 to 21 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-positive patients (alternative to preferred therapy): Oral, IV (off-label route): 200 mg twice daily for 14 to 21 days (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, intravascular infections (off-label use) (IDSA [Pappas 2016]):</b> Fluconazole-resistant/voriconazole-susceptible isolates:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endocarditis, native or prosthetic valve:</i> Oral: 200 to 300 mg twice daily; voriconazole should only be used as step-down therapy in clinically stable, culture-negative patients following initial therapy with an amphotericin B lipid formulation (with or without flucytosine) or an echinocandin; antifungal therapy should continue for at least 6 weeks after valve replacement surgery (longer durations recommended in patients with perivalvular abscesses or other complications).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Implantable cardiac devices (eg, pacemaker. ICD, VAD):</i> Oral: 200 to 300 mg twice daily; voriconazole should only be used as step-down therapy in clinically stable, culture-negative patients following initial therapy with an amphotericin B lipid formulation (with or without flucytosine) or an echinocandin; antifungal therapy should continue for 4 to 6 weeks after device removal (4 weeks for infections limited to generator pockets and at least 6 weeks for infections involving the wires).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, oropharyngeal (fluconazole-refractory) (off-label use): </b>Oral: 200 mg twice daily for up to 28 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coccidioidomycosis in HIV-infected patients (alternative to preferred therapy) (off-label use) (HHS [OI adult 2015]):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild infections (eg, focal pneumonia): 200 mg twice daily; patients who complete initial therapy should be considered for lifelong suppressive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic suppressive therapy: 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coccidioidal meningitis (salvage therapy) (non-HIV infected patients) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 6 mg/kg every 12 hours for two doses, then 4 mg/kg every 12 hours (Cortez 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 200 mg twice daily (IDSA [Galgiani 2016]); limited data (case reports) also report using higher doses (range: 250 mg to 400 mg twice daily) during the treatment course based on clinical response to therapy (Cortez 2003; Proia 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Empiric antifungal therapy (neutropenic fever) (off-label use): </b>IV: Initial: 6 mg/kg every 12 hours for 2 doses; maintenance dose: 4 mg/kg every 12 hours. <b>Note:</b> May consider oral therapy in place of IV therapy, with dosing of 200 to 300 mg orally every 12 hours <b>or</b> weight-based dosing (3 to 4 mg/kg) every 12 hours (IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Scedosporiosis, fusariosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 6 mg/kg every 12 hours for 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: 4 mg/kg every 12 hours for &gt;7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Maintenance dose: <b>Note:</b> If patient has inadequate clinical response, titrate in 50 mg/dose increments for weight &lt;40 kg and 100 mg/dose increments for weight &ge;40 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight &lt;40 kg: 100 mg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight &ge;40 kg: 200 mg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infection prophylaxis in graft-versus-host disease (GVHD) (high-risk patients) (off-label use) (Maertens 2011; Tomblyn 2009; Wingard 2010):</b> <b>Note:</b> The optimal duration of prophylaxis in GVHD has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Weight &gt;40 kg: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Weight &gt;40 kg: 4 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Infection prophylaxis in standard- or high-risk patients with allogeneic hematopoietic stem cell transplant (HSCT) or certain autologous HSCT (off-label use) (Castagna 2012; Maertens 2011; Tomblyn 2009; Wingard 2010): </b> <b>Note:</b> Begin prophylaxis at the start of chemotherapy or the day of transplantation. The ASBMT recommends continuing prophylaxis until engraftment (ie, 30 days) or for 7 days after the ANC reaches &gt;1000 cells/mm<sup>3</sup> (Tomblyn 2009). The IDSA recommends anti-mold prophylaxis in allograft HSCT patients &quot;through the neutropenic period and beyond,&quot; based on a demonstrated survival advantage in patients receiving prophylaxis for 75 days post-HSCT, or until cessation of immunosuppressive therapy (Freifeld 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Weight &gt;40 kg: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Weight &gt;40 kg: 4 mg/kg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis (secondary to contaminated [eg, </b>\n      <b>\n        <i>Exserohilum rostratum</i></b>\n      <b>] steroid products) (off-label use) (CDC [parameningeal] 2012; Kauffman 2013): Note: </b> Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations. Therapy duration is &ge;3 months; trough serum concentrations must be maintained between 2 to 5 mcg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 6 mg/kg every 12 hours. If patient does not improve or has severe disease, consider adding amphotericin B (liposomal).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (only in mild disease in adherent patients whose trough concentrations/response to therapy can be closely monitored): 6 mg/kg every 12 hours (CDC [parameningeal] 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoarticular infection involving the spine, discitis, epidural abscess or vertebral osteomyelitis (secondary to contaminated [eg, </b> <b><i>Exserohilum rostratum</i></b><b>] steroid products) (off-label use) (CDC [osteoarticular] 2012; Kauffman 2013):</b> IV: 6 mg/kg every 12 hours for &ge;3 months. <b>Note:</b> Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations. Trough serum concentrations must be maintained between 2 to 5 mcg/mL. If patient has severe disease, consider adding amphotericin B (liposomal). Patients may be switched to oral therapy if condition has improved or stabilized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Osteoarticular infection not involving the spine (secondary to contaminated [eg,</b> <b><i>Exserohilum rostratum</i></b><b>] steroid products) (off-label use) (CDC [osteoarticular] 2012; Kauffman 2013):</b> <b>Note:</b> Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations. Therapy duration is &ge;3 months. Trough serum concentrations must be maintained between 2 to 5 mcg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours. If patient has severe disease, consider adding amphotericin B (liposomal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral (only in mild disease in adherent patients whose trough concentrations/response to therapy can be closely monitored): 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Talaromyces marneffei</i></b>\n      <b> infection in HIV-infected patients (off-label use) (HHS [OI adult 2015]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute infection in severely ill patients: 6 mg/kg IV every 12 hours for 2 doses, then 4 mg/kg IV every 12 hours for at least 3 days, followed by 200 mg orally twice daily for a maximum of 12 weeks; follow with itraconazole chronic maintenance therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild disease: Oral: 400 mg twice daily for 2 doses, then 200 mg twice daily for a maximum of 12 weeks; follow with itraconazole chronic maintenance therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment in patients with inadequate response:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Maintenance dose may be increased from 3 mg/kg every 12 hours to 4 mg/kg every 12 hours, depending upon condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Maintenance dose may be increased from 200 mg every 12 hours to 300 mg every 12 hours in patients weighing &ge;40 kg (or to 150 mg every 12 hours in patients &lt;40 kg), depending upon condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment in patients unable to tolerate treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Maintenance dose may be reduced from 4 mg/kg every 12 hours to 3 mg/kg every 12 hours, depending upon condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Maintenance dose may be reduced in 50 mg decrements to a minimum dosage of 200 mg every 12 hours in patients weighing &ge;40 kg (or to 100 mg every 12 hours in patients &lt;40 kg), depending upon condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in patients receiving concomitant CYP450 enzyme inducers or substrates:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Efavirenz: Oral: Increase maintenance dose of voriconazole to 400 mg every 12 hours and reduce efavirenz dose to 300 mg once daily; upon discontinuation of voriconazole, return to the initial dose of efavirenz.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Phenytoin:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Increase voriconazole maintenance dose to 5 mg/kg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Increase voriconazole maintenance dose to 400 mg every 12 hours in patients &ge;40 kg (200 mg every 12 hours in patients &lt;40 kg).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234806\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Voriconazole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> In pediatric patients &lt;12 years, bioequivalence between the oral tablet and suspension has not been determined; due to possible shortened gastric transit time in infants and children, absorption of tablets may be different than adults; it is recommended that infants and children &lt;12 years only receive oral suspension formulation [Vfend prescribing information (Europe Medicines Agency) 2013]. Data suggest higher doses (mg/kg) than adults are required in patients &lt;15 years and weighing &lt;50 kg. Although FDA approved for treatment of certain fungal infections in patients &ge;12 years, the manufacturer&rsquo;s dosing may not achieve necessary therapeutic targets and possible suboptimal response in patients &lt;15 years may occur (Friberg 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years (off-label): IV, Oral (oral suspension): Initial: 9 mg/kg/dose every 12 hours followed by monitoring of serum trough concentrations typically initiated after 3 to 5 days; adjust dose to achieve target trough (&gt;1 mcg/mL); median final dosage: 31.5 mg/kg/<b>day</b> (range: 12 to 71 mg/kg/<b>day</b>) divided every 12 hours; dosing based on 2 pharmacokinetic studies that included a total of 17 patients &lt;2 years (Bartenlink 2013; Gerin 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;12 years (off-label; <i>Red Book</i> [AAP 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: IV: 9 mg/kg/dose every 12 hours for 2 doses on day 1</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 8 mg/kg/dose every 12 hours; monitor serum concentrations to maintain trough &gt;2 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral (oral suspension): 9 mg/kg/dose every 12 hours; maximum initial dose: 350 mg/dose; <b>Note:</b> In most patients, oral therapy has not been recommended as initial therapy for treatment; it has been recommended to convert from parenteral to oral therapy only after significant clinical improvement has been observed [Vfend prescribing information (Europe Medicines Agency) 2013].</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents &le;14 years (off-label; Friberg 2012): <b>Note: </b>In this age group, body weight is more important than age in predicting pharmacokinetics</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;50 kg: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 4 to 8 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;50 kg: Loading dose: 6 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 3 to 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: <b>Note: </b>Higher doses may be required if adequate trough concentrations are not achieved; monitor trough concentrations closely</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;50 kg: 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;50 kg: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;15 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Loading dose: 6 mg/kg/dose every 12 hours for 2 doses; followed by a maintenance dose of 3 to 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 200 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis, invasive, including disseminated and extrapulmonary infection; treatment: Note:</b> Duration of therapy should be a minimum of 6 to 12 weeks, although duration is highly dependent on degree/duration of immunosuppression, disease site, and evidence of disease improvement. Monitor trough concentrations in patients with invasive aspergillosis; in pediatric patients &lt;50 kg, therapeutic drug monitoring is critical to ensure efficacy and minimize toxicity; may consider switching to oral therapy once patient is stable and able to tolerate (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years (off-label):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses on day 1, followed by a maintenance dose of 8 mg/kg/dose every 12 hours (Friberg 2012; IDSA [Patterson 2016]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (oral suspension): 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose; higher doses may be required if adequate trough concentrations are not achieved; monitor trough concentrations closely (Friberg 2012; IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents &le;14 years (off-label): <b>Note:</b> In this age group, body weight is more important than age in predicting pharmacokinetics (Friberg 2012; IDSA [Patterson 2016]); monitor trough concentrations closely; higher doses may be required if adequate trough concentrations are not achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 8 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 9 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Loading dose: 6 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 200 to 300 mg every 12 hours <b>or </b>3 to 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;15 years (off-label; IDSA [Patterson 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Loading dose: 6 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 200 to 300 mg every 12 hours <b>or</b> 3 to 4 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, prophylaxis for patients at high risk of invasive candidiasis (eg, AML, recurrent ALL, allogeneic HSCT) (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years (Dvorak 2012; ESCMID [Hope 2012]; Friberg 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses on day 1, followed by a maintenance dose of 8 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (oral suspension): 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents &le;14 years: <b>Note: </b>In this age group, body weight is more important than age in predicting pharmacokinetics (Friberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 8 mg/kg/dose every 12 hours (Dvorak 2012; ESCMID [Hope 2012]; Friberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (ESCMID [Hope 2012]; Friberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 4 mg/kg/dose every 12 hours (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 200 mg every 12 hours (Tomblyn 2009; Wingard 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;15 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 4 mg/kg/dose every 12 hours (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 200 mg every 12 hours (Tomblyn 2009; Wingard 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, invasive; treatment: </b> <b>Note: </b>Voriconazole is considered an alternative therapy and offers little advantage over fluconazole as first-line therapy of candidemia. Step-down therapy to oral voriconazole is recommended only in select clinically stable patients with certain voriconazole-susceptible isolates (eg, <i>C. krusei</i>) and negative repeat cultures (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years (off-label; ESCMID [Hope 2012]; IDSA [Pappas 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses on day 1, followed by a maintenance dose of 8 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (oral suspension): 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents &le;14 years (off label): <b>Note: </b>In this age group, body weight is more important than age in predicting pharmacokinetics (Friberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 8 mg/kg/dose every 12 hours (ESCMID [Hope 2012]; Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (ESCMID [Hope 2012]; Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Loading dose: 400 mg (6 mg/kg/dose) every 12 hours for 2 doses, followed by 200 mg (3 mg/kg/dose) every 12 hours (ESCMID [Hope 2012]; Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 200 mg (3 mg/kg/dose) every 12 hours (ESCMID [Hope 2012]; Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;15 years (off-label):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Loading dose: 400 mg (6 mg/kg/dose) every 12 hours for 2 doses, followed by 200 mg (3 mg/kg/dose) every 12 hours (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 200 mg (3 mg/kg/dose) every 12 hours (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, esophageal (fluconazole-refractory); treatment:</b> Treatment should continue for 14 to 21 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV (off-label): Loading dose: 9 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 8 mg/kg/dose every 12 hours (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (oral suspension): 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents &le; 14 years: <b>Note: </b>In this age group, body weight is more important than age in predicting pharmacokinetics (Friberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV (off-label): Loading dose: 9 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 8 mg/kg/dose every 12 hours (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 kg: IV (off-label), Oral: 200 mg (3 mg/kg/dose) twice daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;15 years: IV (off-label), Oral: 200 mg (3 mg/kg/dose) twice daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, intravascular infections (endocarditis/implantable cardiac devices [eg, pacemaker, ICD, VAD]); treatment (off-label use): Note: </b>Voriconazole should only be used as step-down therapy in clinically stable, culture-negative patients following initial therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years: Oral (oral suspension): 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents &le;14 years: <b>Note:</b> In this age group, body weight is more important than age in predicting pharmacokinetics (Friberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg: Oral: 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge; 50 kg: Oral: 200 to 300 mg (3 to 4 mg/kg/dose) twice daily (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;15 years: Oral: 200 to 300 mg (3 to 4 mg/kg/dose) twice daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, oropharyngeal (fluconazole-refractory); treatment (off-label use): </b>Treatment should continue for up to 28 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years: Oral (oral suspension): 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents &le;14 years: <b>Note: </b>In this age group, body weight is more important than age in predicting pharmacokinetics (Friberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg: Oral: 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 kg: Oral: 200 mg twice daily (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;15 years: Oral: 200 mg twice daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, endophthalmitis (with or without vitritis): </b>  Voriconazole-susceptible isolates (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic therapy: </i>\n      <b>Note: </b>For patients with vitritis or with macular involvement (with or without vitritis), an intravitreal injection of voriconazole or amphotericin B deoxycholate is also recommended (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 8 mg/kg/dose every 12 hours (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral (oral suspension): 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents &le;14 years: <b>Note: </b>In this age group, body weight is more important than age in predicting pharmacokinetics (Friberg 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: Loading dose: 9 mg/kg/dose every 12 hours for 2 doses; followed by maintenance dose of 8 mg/kg/dose every 12 hours (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 9 mg/kg/dose every 12 hours; maximum dose: 350 mg/dose (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: Loading dose: 400 mg (6 mg/kg/dose) every 12 hours for 2 doses, followed by 300 mg (4 mg/kg/dose) twice daily (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 300 mg (4 mg/kg/dose) twice daily (Friberg 2012; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;15 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Loading dose: 400 mg (6 mg/kg/dose) every 12 hours for 2 doses, followed by 300 mg (4 mg/kg/dose) twice daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 300 mg (4 mg/kg/dose) twice daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intravitreal therapy: </i>Patients with vitritis or with macular involvement (with or without vitritis): Children &ge;2 years and Adolescents: Intravitreal: 100 <b>mcg</b> of an extemporaneously prepared solution in 0.1 mL sterile water or NS; concomitant systemic antifungal therapy is also recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234788\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234789\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &ge;50 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;50 mL/minute: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling.  Due to accumulation of the intravenous vehicle (cyclodextrin), the manufacturer recommends the use of oral voriconazole in these patients unless an assessment of the benefit:risk justifies the use of IV voriconazole; if IV therapy is used, closely monitor serum creatinine and change to oral voriconazole when possible.  IV therapy has been used in select patients with CrCl &lt;50 mL/minute using varying doses (median duration of treatment 7 to 10  days) (Neofytos 2012; Oude Lashof 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mild to severe impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis (IHD) with thrice weekly sessions or peritoneal dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous renal replacement therapy (CRRT) (Heintz 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CVVH, CVVHD, and CVVHDF: Loading dose of 400 mg every 12 hours for 2 doses, followed by 200 mg every 12 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234790\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild to moderate impairment (Child-Pugh class A or B): Following standard loading dose, reduce maintenance dosage by 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Should only be used if benefit outweighs risk; monitor closely for toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48999062\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Use ideal body weight (IBW) for most obese patients in weight-based dosing calculations; consider using an adjusted body weight (adjusted body weight=0.4 [total body weight &ndash; IBW] + IBW) in obese patients with life-threatening invasive fungal infections. Confirm selection of an appropriate dose with therapeutic drug monitoring (Eljaaly 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234759\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vfend IV: 200 mg (1 ea) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vfend IV: 200 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vfend: 40 mg/mL (75 mL) [contains sodium benzoate; orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg/mL (75 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vfend: 50 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234745\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234761\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer 1 hour before or 1 hour after a meal. Shake oral suspension for approximately 10 seconds before each use. Enteral tube feedings may decrease oral absorption; may hold tube feedings for 1 hour before and 1 hour after a voriconazole dose (Williams 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 1 to 2 hours (rate not to exceed 3 mg/kg/hour). Do not administer as an IV bolus injection. Do not infuse <b>concomitantly</b> into same line or cannula with other drug infusions. Do not infuse <b>concomitantly</b> even in separate lines or cannulas with concentrated electrolyte solutions or blood products. May be infused simultaneously with nonconcentrated electrolytes or TPN through a separate IV line. If TPN is infused through a multiple lumen catheter, use a different port than used for voriconazole.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravitreal (off-label): Administer an extemporaneously prepared solution of 100 mcg/0.1 mL of voriconazole in sterile water or NS intravitreally (IDSA [Pappas 2016]; IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic (off-label): Administer an extemporaneously prepared voriconazole 10 mg/mL (1%) ophthalmic solution to the affected eye.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133419\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234760\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Treatment of fungal infections:</b> Treatment of invasive aspergillosis; treatment of esophageal candidiasis; treatment of candidemia (in non-neutropenic patients); treatment of disseminated <i>Candida</i> infections of the skin and abdomen, kidney, bladder wall, and wounds; treatment of serious fungal infections caused by <i>Scedosporium apiospermum</i> and <i>Fusarium</i> spp. (including <i>Fusarium solani</i>) in patients intolerant of, or refractory to, other therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25497518\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute myelogenous leukemia (prophylaxis of fungal infections); Allogeneic hematopoietic stem cell transplant (prophylaxis of fungal infections); Allogeneic hematopoietic stem cell transplant patients with graft-versus-host disease (prophylaxis of fungal infections); Aspergillosis, invasive (prophylaxis during prolonged neutropenia); Aspergillosis, ocular; Candidiasis, endophthalmitis; Candidiasis, esophageal; Candidiasis, intravascular infections; Candidiasis, oropharyngeal (fluconazole-refractory); Coccidioidal meningitis (salvage therapy) (non-HIV infected patients); Coccidioidomycosis (treatment/chronic suppressive therapy) in HIV-infected patients (adolescents and adults); Empiric antifungal therapy (neutropenic fever); Fungal meningitis or osteoarticular infections (secondary to contaminated steroid products); Myelodysplastic Syndrome (prophylaxis of fungal infections); Talaromyces marneffei infection in HIV-infected patients (adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14694838\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Voriconazole may be confused with fluconazole, itraconazole, posaconazole</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234751\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Hallucination (2% to 12%; auditory and/or visual and likely serum concentration-dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Visual disturbance (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine (1% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">2% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Tachycardia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Chills (&le;4%), headache (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (&le;7%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypokalemia (&le;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (1% to 5%), vomiting (1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase (4% to 5%), increased serum AST (2% to 4%), increased serum ALT (2% to 3%), cholestatic jaundice (1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Photophobia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;2%, postmarketing, and/or case reports (limited to important or life-threatening): Acute renal failure, adrenocortical insufficiency, agranulocytosis, alopecia, anaphylactoid reaction, anemia (aplastic, hemolytic, macrocytic, megaloblastic, or microcytic), angioedema, anorexia, anuria, arthritis, ascites, ataxia, atrial arrhythmia, atrial fibrillation, atrioventricular block, bacterial infection, bigeminy, blighted ovum, bone marrow depression, bradycardia, brain disease, bundle branch block, cardiac arrest, cardiac failure, cardiomegaly, cardiomyopathy, cellulitis, cerebral edema, cerebral hemorrhage, cerebral ischemia, cerebrovascular accident, chest pain, cholecystitis, cholelithiasis, cholestasis, chromatopsia, color blindness, coma, confusion, convulsions, corneal opacity, cyanosis, deafness, deep vein thrombophlebitis, deep vein thrombosis, delirium, dementia, dental fluorosis, depersonalization, depression, diabetes insipidus, diarrhea, discoid lupus erythematosus, disseminated intravascular coagulation, drowsiness, duodenal ulcer (active), duodenitis, dyspnea, eczema, edema, encephalitis, endocarditis, eosinophilia, erythema multiforme, esophageal ulcer, exfoliative dermatitis, extrapyramidal reaction, extrasystoles, fixed drug eruption, fungal infection, gastric ulcer, gastrointestinal hemorrhage, glucose tolerance decreased, graft versus host disease, Guillain-Barre syndrome, hematemesis, hemorrhagic cystitis, hepatic coma, hepatic failure, hepatitis, hepatomegaly, herpes simplex infection, hydronephrosis, hyperbilirubinemia, hypercholesterolemia, hyper-/hypocalcemia, hyper-/hypoglycemia, hyper-/hypomagnesemia, hyper-/hyponatremia, hyper-/hypotension, hyper-/hypothyroidism, hyperkalemia, hypersensitivity reaction, hyperuricemia, hypophosphatemia, hypoxia, impotence, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased susceptibility to infection, intestinal perforation, intracranial hypertension, jaundice, leukopenia, lymphadenopathy, lymphangitis, maculopapular rash, malignant melanoma, melanosis, multiorgan failure, myasthenia, myocardial infarction, myopathy, nephritis, nephrosis, neuropathy, nocturnal amblyopia, nodal arrhythmia, nodule, nystagmus, oculogyric crisis, optic atrophy, optic neuritis, orthostatic hypotension, osteomalacia, osteonecrosis, osteoporosis, otitis externa, palpitations, pancreatitis, pancytopenia, papilledema, paresthesia, perforated duodenal ulcer, periosteal disease, peripheral edema, peritonitis, petechia, pleural effusion, pneumonia, prolonged bleeding time, prolonged QT interval on ECG, pruritus, pseudomembranous colitis, pseudoporphyria, psoriasis, psychosis, pulmonary edema, pulmonary embolism, purpura, rectal hemorrhage, renal insufficiency, renal tubular necrosis, respiratory distress syndrome, respiratory tract infection, retinal hemorrhage, retinitis, seizure, sepsis, skin discoloration, skin photosensitivity, splenomegaly, squamous cell carcinoma, Stevens-Johnson syndrome, subconjunctival hemorrhage, substernal pain, suicidal ideation, supraventricular extrasystole, supraventricular tachycardia, syncope, thrombocytopenia, thrombophlebitis, thrombotic thrombocytopenic purpura, tongue edema, tonic-clonic seizures, torsades de pointes, toxic epidermal necrolysis, uremia, urinary incontinence, urinary retention, urinary tract infection, urticaria, uterine hemorrhage, uveitis, vaginal hemorrhage, vasodilation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, visual field defect </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234764\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to voriconazole or any component of the formulation; coadministration with astemizole, barbiturates (long acting), carbamazepine, cisapride, efavirenz (&ge;400 mg daily), ergot derivatives (ergotamine and dihydroergotamine), pimozide, quinidine, rifampin, rifabutin, ritonavir (&ge;800 mg daily; also avoid low dose [eg, 200 mg daily] dosing if possible), sirolimus, St John&rsquo;s wort, terfenadine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for imidazole antifungals is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234749\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias/QT prolongation: QT interval prolongation has been associated with voriconazole use; rare cases of arrhythmia (including torsade de pointes), cardiac arrest, and sudden death have been reported, usually in seriously ill patients with comorbidities and/or risk factors (eg, prior cardiotoxic chemotherapy, cardiomyopathy [especially with concomitant heart failure], electrolyte imbalance, or concomitant QTc-prolonging drugs). Also use with caution in patients with potentially proarrhythmic conditions (eg, congenital or acquired QT syndrome, sinus bradycardia, or preexisting symptomatic arrhythmias); correct electrolyte abnormalities (eg, hypokalemia, hypomagnesemia, hypocalcemia) prior to initiating and during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic reactions: Rare cases of malignancy (melanoma, squamous cell carcinoma [SCC]) have been reported in patients with prior onset of severe photosensitivity reactions or exposure to standard dose long-term voriconazole therapy (in lung transplant recipients, SCC increased by ~6% per 60 days with a 28% absolute risk increase at 5 years [Singer 2012]). Other serious exfoliative cutaneous reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme, have also been reported. Patients, including children, should avoid exposure to direct sunlight and should use protective clothing and high SPF sunscreen; may cause photosensitivity, especially with long-term use. Discontinue use in patients who develop an exfoliative cutaneous reaction or a skin lesion consistent with squamous cell carcinoma or melanoma. Periodic total body skin examinations should be performed, particularly with prolonged use. If phototoxic reactions occur, referral to a dermatologist and voriconazole discontinuation should be considered.  If therapy is continued, dermatologic evaluation should be performed on a systematic and regular basis to allow early detection and management of premalignant lesions.  Pediatric patients are at particular risk for phototoxicity (see Special Populations).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic toxicity: Serious (and rarely fatal) hepatic reactions (eg, hepatitis, cholestasis, fulminant failure) have been observed with voriconazole. In lung transplant recipients, median time to hepatic toxicity was 14 days with the majority occurring within 30 days of therapy initiation (Luong 2012). Use with caution in patients with serious underlying medical conditions (eg, hematologic malignancy); hepatic reactions have occurred in patients with no identifiable underlying risk factors. Liver dysfunction is usually reversible upon therapy discontinuation. Monitor serum transaminase and bilirubin at baseline and at least weekly for the first month of treatment. Monitoring frequency can then be reduced to monthly during continued use if no abnormalities are noted. If marked elevations occur compared to baseline, discontinue unless benefit/risk of treatment justifies continued use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infusion-related reactions: Anaphylactoid-type reactions including tachycardia, dyspnea, chest tightness, faintness, nausea, rash, pruritus, fever, sweating and flushing have been observed; symptoms have appeared immediately upon initiating the infusion. Stop infusion for severe reactions or as clinical presentation indicates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular effects: Visual changes, including blurred vision, changes in visual acuity, color perception, and photophobia, are commonly associated with treatment; postmarketing cases of optic neuritis and papilledema (lasting &gt;1 month) have also been reported. Patients should be warned to avoid tasks which depend on vision, including operating machinery or driving. Changes are reversible on discontinuation following brief exposure/treatment regimens (&le;28 days); reversibility following long-term administration has not been evaluated. If treatment continues &gt;28 days, visual function (eg, acuity, visual field, color perception) should be monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal toxicity: Acute renal failure has been observed in severely ill patients; use with caution in patients receiving concomitant nephrotoxic medications. Evaluate renal function (particularly serum creatinine) at baseline and periodically during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skeletal effects: Fluorosis and/or periostitis may occur during long-term therapy. If patient develops skeletal pain and radiologic findings of fluorosis or periostitis, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Toxicity symptoms: Voriconazole demonstrates nonlinear pharmacokinetics. Dose modifications may result in unpredictable changes in serum concentrations and contribute to toxicity. For toxicity, the strongest correlations have been made between voriconazole trough concentrations and neurological and dermatological adverse events (Dolton 2012; Hamada 2012; Mitsani 2012; Park 2012; Soler-Palacin 2012). In these studies, increased toxicity was noted when trough concentrations exceeded threshold values. There are much less data supporting the existence between a cutoff threshold and hepatotoxicity. It is important to note that cutoff trough threshold values ranged widely among studies; however, an upper limit of &lt;5.0 mg/L would be reasonable for most disease states (see CDC recommendations for <i>Exserohilum rostratum</i> in Reference Range section) (CDC 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte abnormalities: Correct electrolyte abnormalities (eg, hypokalemia, hypomagnesemia, hypocalcemia) prior to initiating and during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution; elevated liver function tests and clinical signs of liver damage, such as jaundice, have been associated with voriconazole. Adjustments to maintenance dosing is required in mild to moderate hepatic cirrhosis (Child-Pugh class A and B). In patients with severe hepatic insufficiency use only if the benefit outweighs the potential risk. Evaluate hepatic function (particularly liver function tests and bilirubin) at baseline and periodically during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Monitor pancreatic function in patients (children and adults) at risk for acute pancreatitis (eg, recent chemotherapy or hematopoietic stem cell transplantation). Pancreatitis has occurred in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Avoid the use of IV voriconazole in patients with renal impairment. See &quot;Dosage forms specific issues: Injection: formulation.&quot;  Evaluate renal function (particularly serum creatinine) at baseline and periodically during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric pharmacokinetics: In pediatric patients, voriconazole pharmacokinetics are complex. In patients &gt;14 years of age or 12 to 14 years and weighing &gt;50 kg, data suggest that pharmacokinetics are similar to adults (Friberg 2012). In patients &lt;12 years of age, the full pharmacokinetic profile for voriconazole is not completely defined and for patients &lt;2 years, the data are sparse. In children 2 to &lt;12 years, current data suggest voriconazole undergoes a high degree of variability in exposure with linear elimination at lower doses and nonlinear elimination at higher doses; therefore, to achieve similar AUC as adults, increased dosage is necessary in children  (Friberg 2012; Karlsson 2009; Walsh 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric dermatologic reactions: Frequency of phototoxic reactions is higher in pediatric patients.  Stringent photoprotective measures are necessary in children due to the risk of squamous cell carcinoma.  In children experiencing photoaging injuries (eg, lentigines or ephelides), avoidance of sun and dermatologic follow-up are warranted even after treatment is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection: Avoid/limit use of IV formulation in patients with moderate to severe renal impairment (CrCl &lt;50 mL/minute); injection contains excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin [SBECD]), which may accumulate, although the clinical significance of this finding is uncertain (Luke 2010); consider using oral voriconazole in these patients unless benefit of injection outweighs the risk. If injection is used in patients CrCl &lt;50 mL/minute, monitor serum creatinine closely; if increases occur, consider changing therapy to oral voriconazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Lactose: Tablets contain lactose; avoid administration in hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Sucrose: Suspension contains sucrose; use caution with fructose intolerance, sucrase-isomaltase deficiency, or glucose-galactose malabsorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monitoring: Evaluate renal function (particularly serum creatinine) and hepatic function (particularly liver function tests and bilirubin) at baseline and periodically during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234816\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (moderate), CYP2C9 (moderate), CYP3A4 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234753\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10118&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Abemaciclib.  Management: In patients taking abemaciclib at a dose of 200 mg or 150 mg twice daily, reduce the dose to 100 mg twice daily when combined with strong CYP3A4 inhibitors. In patients taking abemaciclib 100 mg twice daily, decrease the dose to 50 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alitretinoin (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with strong CYP3A4 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALPRAZolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ALPRAZolam.  Management: Consider using an alternative agent that is less likely to interact. If combined, monitor for increased therapeutic/toxic effects of alprazolam if combined with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May decrease the serum concentration of Voriconazole. Management: Concurrent use of voriconazole with antihepaciviral combination products should be avoided unless the patient-specific benefit/risk ratio justifies the use of voriconazole. Decreased efficacy of voriconazole is possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antineoplastic Agents (Vinca Alkaloids): Voriconazole may enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Please refer to the full interaction monograph for details concerning the recommended dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Astemizole: Voriconazole may increase the serum concentration of Astemizole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: May decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir. Management: Voriconazole should not be used in a patient who is being treated with ritonavir-boosted atazanavir unless the benefits of the combination outweigh the potential risks.  Extra monitoring for both loss of effectiveness and toxicity is warranted.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Voriconazole may increase the serum concentration of AtorvaSTATin.  Management: Monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment, and reduce atorvastatin dose when possible. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: Voriconazole may increase the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Voriconazole.<b> Exceptions: </b>Methohexital; PENTobarbital; Secobarbital; Thiopental.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barnidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Barnidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bictegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Blonanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Boceprevir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with a strong CYP3A4 inhibitor; reduce to 25% of usual if used with both a moderate CYP3A4 inhibitor and a CYP2D6 inhibitor, or if a strong CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If combination cannot be avoided, reduce the brigatinib dose by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bromocriptine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Busulfan. Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabazitaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel.  Management: Concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided when possible.  If such a combination must be used, consider a 25% reduction in the cabazitaxel dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.  Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcifediol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.<b> Exceptions: </b>Clevidipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabidiol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Voriconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cariprazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cariprazine.  Management: Cariprazine dose reductions of 50% are required; specific recommended management varies slightly for those stable on cariprazine versus those just starting cariprazine.  See prescribing information or full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ceritinib.  Management:  If such combinations cannot be avoided, the ceritinib dose should be reduced by approximately one-third (to the nearest 150 mg).  Resume the prior ceritinib dose after cessation of the strong CYP3A4 inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May increase the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving strong inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride. Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a moderate CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: Voriconazole may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Voriconazole.  Management: Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients who are being treated with cobicistat-containing products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Copanlisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Copanlisib.  Management: If concomitant use of copanlisib and strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg. Monitor patients for increased copanlisib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Orally inhaled fluticasone propionate with a strong CYP3A4 inhibitor is not recommended.<b> Exceptions: </b>Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Systemic). <b> Exceptions: </b>MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic). Fluconazole and isavuconazonium considerations are addressed in separate monographs. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Substrates (High risk with Inhibitors): CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); AmLODIPine; Benzhydrocodone; Buprenorphine; Gefitinib; HYDROcodone; Praziquantel; Telithromycin; Vinorelbine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dabrafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Daclatasvir.  Management: Decrease the daclatasvir dose to 30 mg once daily if combined with a strong CYP3A4 inhibitor.  No dose adjustment is needed when daclatasvir is used with darunavir/cobicistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dapoxetine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of Voriconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Voriconazole may enhance the QTc-prolonging effect of Dasatinib. Voriconazole may increase the serum concentration of Dasatinib.  Management: This combination should be avoided; consider reducing dasatinib dose if voriconazole must be used. If using dasatinib 100 mg/day, consider reduction to 20 mg/day; if using dasatinib 140 mg/day, consider reduction to 40 mg/day.  Monitor ECG closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Delamanid.  Management: Increase electrocardiogram (ECG) monitoring frequency if delamanid is combined with strong CYP3A4 inhibitors because the risk for QTc interval prolongation may be increased. Continue frequent ECG assessments throughout the full delamanid treatment period.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Ophthalmic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dexamethasone (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): Voriconazole may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used with voriconazole.  Arthrotec (diclofenac and misoprostol) labeling recommends limiting the total daily dose to a maximum of 50 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Topical): Voriconazole may increase the serum concentration of Diclofenac (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dihydroergotamine: Voriconazole may increase the serum concentration of Dihydroergotamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOCEtaxel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOCEtaxel.  Management: Avoid the concomitant use of docetaxel and strong CYP3A4 inhibitors when possible. If combined use is unavoidable, consider a 50% docetaxel dose reduction and monitor for increased docetaxel toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Efavirenz. Management: Use of standard doses of these drugs is contraindicated.  The voriconazole oral maintenance dose should be increased to 400 mg every 12 hours, and the efavirenz dose should be reduced to 300 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eliglustat.  Management: Use should be avoided under some circumstances.  See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Voriconazole may increase the serum concentration of Elvitegravir.  Management: Careful consideration of the risk/benefit ratio for voriconazole use is recommended prior to its use in patients treated with elvitegravir-containing products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Voriconazole may increase the serum concentration of Eplerenone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergoloid Mesylates: Voriconazole may increase the serum concentration of Ergoloid Mesylates. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergonovine: Voriconazole may increase the serum concentration of Ergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergotamine: Voriconazole may increase the serum concentration of Ergotamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estazolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estazolam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Voriconazole may decrease the metabolism of Estrogen Derivatives (Contraceptive). Estrogen Derivatives (Contraceptive) may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eszopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eszopiclone.  Management: Limit the eszopiclone dose to 2 mg daily when combined with strong CYP3A4 inhibitors and monitor for increased eszopiclone effects and toxicities (eg, somnolence, drowsiness, CNS depression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etizolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Etizolam.  Management: Consider use of lower etizolam doses when using this combination; specific recommendations concerning dose adjustment are not available.  Monitor clinical response to the combination closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Applicable Isavuconazonium considerations are addressed in separate monographs. Etravirine may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole.  Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: Voriconazole may increase the serum concentration of Everolimus. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evogliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Voriconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).  Management: Use of orally inhaled fluticasone propionate with strong CYP3A4 inhibitors is not recommended.  Use of orally inhaled fluticasone furoate with strong CYP3A4 inhibitors should be done with caution.  Monitor patients using such a combination more closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Voriconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: Voriconazole may increase the serum concentration of Ibrutinib.  Management: Ibrutinib dose reductions are required when combined with voriconazole. Dose recommendations depend on the indication for ibrutinib and the voriconazole dose. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibuprofen: Voriconazole may increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Idelalisib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imidafenacin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imidafenacin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Strong) may increase isavuconazole serum concentrations.  Management: Combined use is considered contraindicated per US labeling. Lopinavir/ritonavir (and possibly other uses of ritonavir doses less than 400 mg every 12 hours) is treated as a possible exception to this contraindication despite strongly inhibiting CYP3A4.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib adult dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lercanidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May decrease the serum concentration of Voriconazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levobupivacaine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levobupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levomilnacipran: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran.  Management: Do not exceed a maximum adult levomilnacipran dose of 80 mg/day in patients also receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May decrease the serum concentration of Voriconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan. Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of Voriconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macitentan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inhibitors. If combined, monitor closely for increased manidipine effects and toxicities. Manidipine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MedroxyPROGESTERone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MedroxyPROGESTERone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meloxicam: Voriconazole may increase the serum concentration of Meloxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Voriconazole may increase the serum concentration of Methadone.  Management: Methadone dose reduction may be necessary when used with voriconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylergonovine: Voriconazole may increase the serum concentration of Methylergonovine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose reduction in patients receiving strong CYP3A4 inhibitors and monitor for increased steroid related adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midostaurin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Midostaurin.  Management: Seek alternatives to the concomitant use of midostaurin and strong CYP3A4 inhibitors if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MiFEPRIStone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 600 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mirodenafil.  Management: Consider using a lower dose of mirodenafil when used with strong CYP3A4 inhibitors. Monitor for increased mirodenafil effects/toxicities with the use of this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Voriconazole may increase the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olaparib.  Management: Avoid use of strong CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxybutynin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Oxybutynin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: Voriconazole may enhance the adverse/toxic effect of OxyCODONE. Voriconazole may increase the serum concentration of OxyCODONE.  Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Panobinostat.  Management: Reduce the panobinostat dose to 10 mg when it must be used with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parecoxib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Parecoxib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PAZOPanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Applicable Isavuconazonium considerations are addressed in separate monographs. Phenytoin may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic).  Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimavanserin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimavanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may enhance the arrhythmogenic effect of Pimozide. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Pimozide. This increase in serum concentrations may lead to QTc interval prolongation and ventricular arrhythmias.  Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperaquine: CYP3A4 Inhibitors (Strong) may enhance the QTc-prolonging effect of Piperaquine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Piperaquine.  Management: Avoid the concomitant use of piperaquine and strong CYP3A4 inhibitors when possible. If this combination cannot be avoided, frequent ECG monitoring is recommended due to the increased risk for QTc prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PONATinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PONATinib.  Management: Per ponatinib U.S. prescribing information, the adult starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pranlukast: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pranlukast. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Praziquantel: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): CYP3A4 Inhibitors (Strong) may increase the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Voriconazole may increase the serum concentration of Progestins (Contraceptive). Progestins (Contraceptive) may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: Voriconazole may increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QUEtiapine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of QUEtiapine.  Management: In quetiapine treated patients, reduce the quetiapine dose to one sixth of the regular dose following strong CYP3A4 inhibitor initiation. In patients receiving strong CYP3A4 inhibitors, initiate quetiapine at the lowest dose and up-titrate as needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine. Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Radotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine. Fluconazole and isavuconazonium considerations are addressed in separate monographs. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Reboxetine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide.  Management: The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retapamulin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Retapamulin.  Management: Avoid this combination in patients less than 2 years old.  No action is required in other populations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reverse Transcriptase Inhibitors (Non-Nucleoside): May decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).<b> Exceptions: </b>Delavirdine; Etravirine; Rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribociclib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ribociclib.  Management: Avoid use of ribociclib with strong CYP3A4 inhibitors when possible; if combined use cannot be avoided, reduce ribociclib dose to 400 mg once daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: Voriconazole may increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of Voriconazole. Management: Concurrent voriconazole and high-dose ritonavir (adult doses of 400 mg every 12 hrs or greater) is contraindicated.  Voriconazole with lower-dose ritonavir should be avoided unless benefits outweigh risk of inadequate voriconazole concentrations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rupatadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: This combination should be avoided under some circumstances. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SAXagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: Voriconazole may increase the serum concentration of Sildenafil.  Management: Concurrent voriconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent voriconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Voriconazole may increase the serum concentration of Sirolimus. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Solifenacin. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: The manufacturer recommends not exceeding 5 mg daily of solifenacin during concomitant therapy with ketoconazole, or other potent CYP3A4 enzyme inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Voriconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUFentanil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Voriconazole may increase the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of SUNItinib. Applicable Isavuconazonium considerations are addressed in separate monographs.  Management: Consider a reduced dose of sunitinib (minimum of 37.5 mg daily) during concomitant use. Concurrent use with itraconazole is not recommended per itraconazole labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Suvorexant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Voriconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: When starting voriconazole in patients already receiving tacrolimus, reduce tacrolimus dose to one-third of the original dose. Monitor tacrolimus blood levels closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical). Applicable Isavuconazonium considerations are addressed in separate monographs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: Voriconazole may increase the serum concentration of Tadalafil. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tasimelteon: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: Voriconazole may increase the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Voriconazole. Telaprevir may increase the serum concentration of Voriconazole.  Management: Concurrent use of telaprevir and voriconazole should be avoided due to the uncertain impact on drug concentrations and effects unless the benefit/risk ratio justifies its use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Telithromycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Temsirolimus.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inhibitors whenever possible. If combined, decrease temsirolimus dose to 12.5 mg per week and monitor patients for increased temsirolimus effects and toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Voriconazole may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tezacaftor.  Management: When combined with strong CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be administered in the morning, twice a week, approximately 3 to 4 days apart. No evening doses of ivacaftor (150 mg) alone should be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended adult dose of tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triazolam: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triazolam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Udenafil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combo should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Valbenazine.  Management: Reduce the valbenazine dose to 40 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vardenafil: Voriconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 2.5 mg per 24 hours  in patients receiving concurrent therapy with strong CYP3A4 inhibitors, such as voriconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Venetoclax.  Management: These combinations are contraindicated during venetoclax initiation and ramp-up. In patients receiving steady venetoclax doses after completing ramp-up, reduce the venetoclax by at least 75% if strong CYP3A4 inhibitor use cannot be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venlafaxine: Voriconazole may enhance the adverse/toxic effect of Venlafaxine. Voriconazole may increase the serum concentration of Venlafaxine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg daily in patients receiving strong CYP3A4 inhibitors. The original vilazodone dose can be resumed following discontinuation of the strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Voriconazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone.  Management: The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234780\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Food may decrease voriconazole absorption.  Management: Oral voriconazole should be taken 1 hour before or 1 hour after a meal. Maintain adequate hydration unless instructed to restrict fluid intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234765\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Voriconazole can cause fetal harm when administered to a pregnant woman. Voriconazole was teratogenic and embryotoxic in animal studies, and lowered plasma estradiol in animal models. Women of childbearing potential should use effective contraception during treatment. Should be used in pregnant woman only if benefit to mother justifies potential risk to the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234766\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if voriconazole is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234757\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic function at initiation, weekly during the first month and monthly during course of treatment; renal function; serum electrolytes (particularly calcium, magnesium and potassium) prior to initiation and during therapy; visual function (visual acuity, visual field and color perception) if treatment course continues &gt;28 days; phototoxic reactions (especially in pediatric patients); pancreatic function (in patients at risk for acute pancreatitis); total body skin examination yearly (more frequently if lesions noted). Monitoring of serum trough concentrations is recommended in the following infections: invasive aspergillosis treatment (and prolonged prophylaxis); endophthalmitis; meningitis or osteoarticular infections due to <i>Exserohilum rostratum </i>(CDC 2012; Riddle 2011; IDSA [Patterson 2016]). For other infections, consider obtaining voriconazole trough level to assure therapeutics serum concentrations in patients failing therapy or in those exhibiting signs of toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitoring of serum trough concentrations is recommended in the following infections: invasive aspergillosis treatment (and prolonged prophylaxis); endophthalmitis; meningitis or osteoarticular infections due to <i>Exserohilum rostratum </i>(CDC 2012; Riddle 2011; IDSA [Patterson 2016]). For other infections, consider obtaining voriconazole trough level to assure therapeutics serum concentrations in patients failing therapy or in those exhibiting signs of toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For meningitis or osteoarticular infections due to <i>Exserohilum rostratum</i>, the CDC recommends obtaining a trough serum concentration on day 5 of therapy and weekly thereafter for the initial 4 to 6 weeks of therapy or when dosing adjustments are made (CDC 2012). For invasive aspergillosis, IDSA recommends monitoring trough serum concentrations after steady state has been reached (4 to 7 days after therapy initiation); the need for continued or repeat monitoring is a patient specific decision influenced by many factors (eg, infection severity, cost, assay availability) (IDSA [Patterson 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23620970\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Refer to Additional Information section for detailed discussion of these data and data in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Trough recommendations in adult patients:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invasive aspergillosis (IDSA [Patterson 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Efficacy: &gt;1 to 1.5 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Minimize toxicity: &lt;5 to 6 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endophthalmitis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Goal: Trough levels between 2 and 5 mcg/mL (Riddell 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Meningitis or osteoarticular infections for <i>Exserohilum rostratum</i> (CDC 2012): 2 to 5 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Other infections (Dolton 2012; Hamada 2012; Mitsani 2012; Park 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Efficacy: &gt;1.0 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Minimize toxicity: &lt;4.0 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic range in adult patients (CDC 2012; Dolton 2012; Hamada 2012; Mitsani 2012; Park 2012; Tomblyn 2009): 1 to 5 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234748\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with fungal cytochrome P450 activity (selectively inhibits 14-alpha-lanosterol demethylation), decreasing ergosterol synthesis (principal sterol in fungal cell membrane) and inhibiting fungal cell membrane formation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234763\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Overall, in pediatric patients, voriconazole pharmacokinetics are complex. In adolescents &gt;14 years and pediatric patients 12 to 14 years and weighing &gt;50 kg, data suggests that pharmacokinetics are similar to adults (Friberg 2012). In pediatric patients &lt;12 years, the full pharmacokinetic profile for voriconazole is not completely defined and for patients &lt;2 years, the data is sparse. In children 2 to &lt;12 years, current data suggests voriconazole undergoes a high degree of variability in exposure with linear elimination at lower doses and nonlinear at higher doses; therefore, to achieve similar AUC as adults, higher mg/kg dosing is necessary in children (Friberg 2012; Karlsson 2009; Walsh 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Extensive tissue distribution; CSF concentration ~50% of plasma concentration (Walsh 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;12 years: Biphasic, V<sub>d</sub> (central): 0.81 L/kg; V<sub>d</sub> (peripheral): 2.2 L/kg (Karlsson 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 4.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 58%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, via CYP2C19 (major pathway) and CYP2C9 and CYP3A4 (less significant); saturable (may demonstrate nonlinearity); the N-oxide major metabolite has minimal antifungal activity; CYP2C19 exhibits genetic polymorphism (15% to 20% Asians may be poor metabolizers of voriconazole; 3% to 5% Caucasians and African Americans may be poor metabolizers). In children 2 to 12 years, metabolic clearance is faster than in adults (Walsh 2010). In children 2 to 12 years, the majority of data has shown that the pharmacokinetic parameters of voriconazole are affected by a patient's CYP2C19 genotype (Hicks 2014; Narita 2013; Wang 2014) although, an initial report suggested CYP2C19 genotype had no apparent effect on exposure in children (Driscoll 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years: Reported range highly variable: ~45% to 64% (Friberg 2012; Karlsson 2009) and values as high as 80% have been reported (Neely 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 96%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Variable, dose-dependent. <b>Note:</b> Steady-state trough concentrations are achieved within 1 day when an IV loading dose is administered and 5 days if no loading dose is used.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years: Median: 1.1 hours (range: 0.73 to 8.03 hours) (Driscoll 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;2% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324109\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Vfend IV Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (1): $179.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Voriconazole Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (1): $152.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Vfend Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (75 mL): $2,541.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Voriconazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (75 mL): $1,055.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Vfend Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $1,110.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $4,441.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Voriconazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $376.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $1,507.35</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234768\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cantex (TR);</li>\n      <li>Progil (BD);</li>\n      <li>Varcon (BD);</li>\n      <li>VFEND (AE, AR, AT, AU, BE, BG, BH, BM, BR, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, ZA);</li>\n      <li>Vfend (BB);</li>\n      <li>Vonaz (LK);</li>\n      <li>Vorcum (VE);</li>\n      <li>Voricon (BD);</li>\n      <li>Vornal (HR);</li>\n      <li>Vorytab (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartelink IH, Wolfs T, Jonker M, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. <i>Antimicrob Agents Chemother.</i> 2013;57(1):235-240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/23114771/pubmed\" target=\"_blank\" id=\"23114771\">23114771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Breit SM, Hariprasad SM, Mieler WF, et al, &ldquo;Management of Endogenous Fungal Endophthalmitis With Voriconazole and Caspofungin,&rdquo; <i>Am J Ophthalmol</i>, 2005, 139(1):135-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/15652837/pubmed\" target=\"_blank\" id=\"15652837\">15652837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castagna L, Bramanti S, Sarina B, et al. ECIL 3-2009 update guidelines for antifungal management [published online ahead of print August 8, 2011]. <i>Bone Marrow Transplant</i>. 2012;47(6):866.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/21822314/pubmed\" target=\"_blank\" id=\"21822314\">21822314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Interim Treatment Guidance for Central Nervous System (CNS) and Parameningeal Infections Associated With Injection of Contaminated Steroid Products,&rdquo; October 23, 2012. Available at <a href=\"http://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html\" target=\"_blank\">http://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Interim Treatment Guidance for Osteoarticular Infections Associated With Injection of Contaminated Steroid Products,&rdquo; October 23, 2012. Available at <a href=\"http://www.cdc.gov/hai/outbreaks/clinicians/interim_guidance_osteoarticular_infections.html\" target=\"_blank\">http://www.cdc.gov/hai/outbreaks/clinicians/interim_guidance_osteoarticular_infections.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20634495\"></a>Cordonnier C, Rovira M, Maertens J, et al; Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group; Infectious Diseases Working party, European Group for Blood and Marrow Transplantation. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. <i>Haemotologica</i>. 2010;95(10):1762-1768.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/20634495/pubmed\" target=\"_blank\" id=\"20634495\">20634495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12802765\"></a>Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. <i>Clin Infect Dis</i>. 2003;36(12):1619-1622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/12802765/pubmed\" target=\"_blank\" id=\"12802765\">12802765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cowen EW, Nguyen JC, Miller DD, et al, &ldquo;Chronic Phototoxicity and Aggressive Squamous Cell Carcinoma of the Skin in Children and Adults During Treatment With Voriconazole,&rdquo; <i>J Am Acad Dermatol</i>, 2010, 62(1):31-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19896749/pubmed\" target=\"_blank\" id=\"19896749\">19896749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dodds-Ashley ES, Zaas AK, Fang AF, et al, &ldquo;Comparative Pharmacokinetics of Voriconazole Administered Orally as Either Crushed or Whole Tablets,&rdquo; <i>Antimicrob Agents Chemother</i>, 2007, 51(3):877-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/17145785/pubmed\" target=\"_blank\" id=\"17145785\">17145785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring [published online ahead of print July 2, 2012]. <i>Antimicrob Agents Chemother</i>. 2012;56(9):4793-4799.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22751544/pubmed\" target=\"_blank\" id=\"22751544\">22751544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Driscoll TA, Yu LC, Frangoul H, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. <i>Antimicrob Agents Chemother</i>. 2011;55(12):5770-5779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/21968355/pubmed\" target=\"_blank\" id=\"21968355\">21968355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. <i>Antimicrob Agents Chemother</i>. 2009;53(2):798-799. doi: 10.1128/AAC.01126-08.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19001119/pubmed\" target=\"_blank\" id=\"19001119\">19001119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durand ML, Kim IK, D&rsquo;Amico DJ, et al, &ldquo;Successful Treatment of Fusarium Endophthalmitis with Voriconazole and Aspergillus Endophthalmitis With Voriconazole Plus Caspofungin,&rdquo; <i>Am J Ophthalmol</i>, 2005, 140(3):552-554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/16139017/pubmed\" target=\"_blank\" id=\"16139017\">16139017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dvorak CC, Fisher BT, Sung L, et al. Antifungal prophylaxis in pediatric hematology/oncology: new choices &amp; new data. <i>Pediatr Blood Cancer</i>. 2012;59(1):21-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22102607/pubmed\" target=\"_blank\" id=\"22102607\">22102607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eljaaly K, Nix D. Voriconazole dosing in obese patients. <i>Clin Infect Dis</i>. 2016;63(3):286-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/27114378/pubmed\" target=\"_blank\" id=\"27114378\">27114378</a>]</span><span class=\"doi\">10.1093/cid/ciw252</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. <i>Antimicrob Agents Chemother</i>. 2012;56(6):3032-3042.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22430956/pubmed\" target=\"_blank\" id=\"22430956\">22430956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. <i>Clin Infect Dis</i>. 2016;63(6):e112-e146. doi: 10.1093/cid/ciw360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/27470238/pubmed\" target=\"_blank\" id=\"27470238\">27470238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerin M, Mahlaoui N, Elie C, et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. <i>Ther Drug Monit.</i> 2011;33(4):464-466.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/21743382/pubmed\" target=\"_blank\" id=\"21743382\">21743382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis [published online ahead of print January 11, 2012]. <i>J Infect Chemother</i>. 2012;18(4):501-507.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22231601/pubmed\" target=\"_blank\" id=\"22231601\">22231601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hariprasad SM, Mieler WF, Holz ER, et al, &ldquo;Determination of Vitreous, Aqueous, and Plasma Concentration of Orally Administered Voriconazole in Humans,&rdquo; <i>Arch Ophthalmol</i>, 2004, 122(1):42-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/14718293/pubmed\" target=\"_blank\" id=\"14718293\">14718293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herbrecht R, Denning DW, Patterson TF, et al, &quot;Voriconazole Versus Amphotericin B for Primary Therapy of Invasive Aspergillosis,&quot; <i>N Engl J Med</i>, 2002, 347(6):408-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/12167683/pubmed\" target=\"_blank\" id=\"12167683\">12167683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hicks JK, Crews KR, Flynn P, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. <i>Pharmacogenomics.</i> 2014;15(8):1065-1078.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/25084200/pubmed\" target=\"_blank\" id=\"25084200\">25084200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. September 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed October 8, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoenigl M, Krause R. Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis. <i>Curr Pharm Des</i>. 2013;19(20):3648-3668. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/23278539/pubmed\" target=\"_blank\" id=\"23278539\">23278539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hope WW, Castagnola E, Groll AH, et al. ESCMID guideline for the diagnosis and management of <i>Candida</i> diseases 2012: prevention and management of invasive infections in neonates and children caused by <i>Candida spp</i>. <i>Clin Microbiol Infect</i>. 2012;18(Suppl 7):38-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/23137136/pubmed\" target=\"_blank\" id=\"23137136\">23137136</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies [published online ahead of print December 15, 2008]. <i>Antimicrob Agents Chemother</i>. 2009;53(3):935-944.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19075073/pubmed\" target=\"_blank\" id=\"19075073\">19075073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23083312\"></a>Kauffman CA, Pappas PG, Patterson TF, &ldquo;Fungal Infections Associated With Contaminated Methylprednisolone Injections: Preliminary Report,&rdquo; <i>N Engl J Med</i>, 2013, 368(26):2495-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/23083312/pubmed\" target=\"_blank\" id=\"23083312\">23083312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous <i>Aspergillus endophthalmitis</i>. <i>Ophthalmology</i>. 2006;113(7):1184-1186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/16713628/pubmed\" target=\"_blank\" id=\"16713628\">16713628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kullberg BJ, Sobel JD, Ruhnke M, et al, &ldquo;Voriconazole Versus a Regimen of Amphotericin B Followed by Fluconazole for Candidaemia in Non-Neutropenic Patients: A Randomised Non-Inferiority Trial,&rdquo; <i>Lancet</i>, 2005, 366(9495):1435-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/16243088/pubmed\" target=\"_blank\" id=\"16243088\">16243088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).<i> J Pharm Sci</i>. 2010;99(8):3291-3301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/20213839/pubmed\" target=\"_blank\" id=\"20213839\">20213839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. <i>Am J Transplant</i>. 2012;12(7):1929-1935.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22486950/pubmed\" target=\"_blank\" id=\"22486950\">22486950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20661235\"></a>Maertens J, Marchetti O, Herbrecht R, et al; Third European Conferences on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoetic stem cell transplant recipients: summary of the ECIL 3--2099 update [published online ahead of print July 26, 2010]. <i>Bone Marrow Transplant</i>. 2011;46(5):709-718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/20661235/pubmed\" target=\"_blank\" id=\"20661235\">20661235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haemotology and Oncology [published online ahead of print May 23, 2009]. <i>Eur J Cancer</i>. 2009;45(14):2462-2472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19467584/pubmed\" target=\"_blank\" id=\"19467584\">19467584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19956980\"></a>Mattiuzzi GN, Cortes J, Alvarado G, et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome [published online ahead of print December 3, 2009]. <i>Support Care Cancer</i>. 2011;19(1):19-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19956980/pubmed\" target=\"_blank\" id=\"19956980\">19956980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCarthy KL, Playford EG, Looke DF, et al. Severe Photosensitivity Causing Multifocal Squamous Cell Carcinomas Secondary to Prolonged Voriconazole Therapy. <i>Clin Infect Dis</i>. 2007;44(5):e55-e56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/17278050/pubmed\" target=\"_blank\" id=\"17278050\">17278050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller DD, Cowen EW, Nguyen JC, et al, &ldquo;Melanoma Associated With Long-Term Voriconazole Therapy: A New Manifestation of Chronic Photosensitivity,&rdquo; <i>Arch Dermatol</i>, 2010, 146(3): E1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/20083676/pubmed\" target=\"_blank\" id=\"20083676\">20083676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity [published online ahead of print February 13, 2012]. <i>Antimicrob Agents Chemother</i>. 2012;56(5):2371-2377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22330924/pubmed\" target=\"_blank\" id=\"22330924\">22330924</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mofenson LM, Brady MT, Danner SP, et al; Centers for Disease Control and Prevention, National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America; Pediatric Infectious Diseases Society; American Academy of Pediatrics. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <i>MMWR Recomm Rep</i>. 2009;58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Narita A, Muramatsu H, Sakaguchi H, et al. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children [published correction appears in <i>J Pediatr Hematol Oncol</i>. 2014 Apr;36(3):252]. <i>Pediatr Hematol Oncol</i>. 2013;35(5):e219-223.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/23588332/pubmed\" target=\"_blank\" id=\"23588332\">23588332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neely M, Rushing T, Kovacs A, et al, &quot;Voriconazole Pharmacokinetics and Pharmacodynamics in Children,&quot; Clin Infect Dis, 2010, 50(1):27-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19951112/pubmed\" target=\"_blank\" id=\"19951112\">19951112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neofytos D, Lombardi LR, Shields RK, et al. Administration of voriconazole in patients with renal dysfunction. <i>Clin Infect Dis</i>. 2012;54(7):913-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22267716/pubmed\" target=\"_blank\" id=\"22267716\">22267716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oude Lashof AM, Sobel JD, Ruhnke M, et al. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. <i>Antimicrob Agents Chemother</i>. 2012;56(6):3133-3137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22450974/pubmed\" target=\"_blank\" id=\"22450974\">22450974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial [published online ahead of print July 3, 2012]. <i>Clin Infect Dis</i>. 2012;55(8):1080-1087.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22761409/pubmed\" target=\"_blank\" id=\"22761409\">22761409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html.27365388</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prajna NV, Mascarenhas J, Krishnan T, Reddy PR, Prajna L, Srinivasan M, Vaitilingam CM, et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. <i>Arch Ophthalmol</i>. 2010;128(6):672-678. doi: 10.1001/archophthalmol.2010.102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/20547942/pubmed\" target=\"_blank\" id=\"20547942\">20547942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, Raghavan A; Mycotic Ulcer Treatment Trial Group, et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. <i>JAMA Ophthalmol</i>. 2013;131(4):422-429.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/23710492/pubmed\" target=\"_blank\" id=\"23710492\">23710492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15155250\"></a>Proia LA, Tenorio AR. Successful use of voriconazole for treatment of <i>Coccidioides menigitis</i>. <i>Antimicrob Agents Chemother</i>. 2004;48(6):2341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/15155250/pubmed\" target=\"_blank\" id=\"15155250\">15155250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. <i>Clin Infect Dis</i>. 2011;52(5):648-653. doi: 10.1093/cid/ciq204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/21239843/pubmed\" target=\"_blank\" id=\"21239843\">21239843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatr Blood Cancer</i>. 2014;61:393-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/24424789/pubmed\" target=\"_blank\" id=\"24424789\">24424789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients [published online ahead of print April 6, 2012]. <i>J Heart Lung Transplant</i>. 2012;31(7):694-699.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22484291/pubmed\" target=\"_blank\" id=\"22484291\">22484291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soler-Palac&iacute;n P, Frick MA, Mart&iacute;n-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study [published online ahead of print December 21, 2011]. <i>J Antimicrob Chemother</i>. 2012;67(3):700-706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/22190607/pubmed\" target=\"_blank\" id=\"22190607\">22190607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group, et al. Guidelines for preventing infectious complications among hematopoeitc cell transplant recipients: a global perspective [published correction appears in <i>Biol Blood Marrow Transplant</i>. 2012;16(2):294]. <i>Biol Blood Marrow Transplant</i>. 2009;15(1):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17822770\"></a>Vehreschild JJ, B&ouml;hme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukemia (AML) [published online ahead of print September 6, 2007]. <i>J Infect</i>. 2007;55(5):445-449.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/17822770/pubmed\" target=\"_blank\" id=\"17822770\">17822770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vfend (voriconazole) [prescribing information]. New York, NY: Pfizer; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vfend (voriconazole) [product monograph]. Sandwich, Kent CT13 9NJ, United Kingdom: Pfizer Limited; March 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vfend (voriconazole) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Anaissie EJ, Denning DW, et al; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;46(3):327-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/18177225/pubmed\" target=\"_blank\" id=\"18177225\">18177225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Karlsson MO, Driscoll T. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. <i>Antimicrob Agents Chemother</i>. 2004;48(6):2166-2172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/15155217/pubmed\" target=\"_blank\" id=\"15155217\">15155217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Pappas P, Winston DJ et al, &quot;Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever,&quot; <i>N Engl J Med</i>, 2002, 346(4):225-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/11807146/pubmed\" target=\"_blank\" id=\"11807146\">11807146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang T, Chen S, Sun J, et al. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.<i> J Antimicrob Chemother</i>. 2014;69(2):463-470.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/24084636/pubmed\" target=\"_blank\" id=\"24084636\">24084636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams D. The effect of enteral nutrition supplements on serum voriconazole levels. <i>J Oncol Pharm Pract</i>. 2012;18(1):128-131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/21733905/pubmed\" target=\"_blank\" id=\"21733905\">21733905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20826719\"></a>Wingard JR, Carter SL, Walsh TJ, et al; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoetic cell transplantation [published online ahead of print September 8, 2010]. <i>Blood</i>. 2010;116(24):5111-5118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/voriconazole-drug-information/abstract-text/20826719/pubmed\" target=\"_blank\" id=\"20826719\">20826719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zonios DI, Gea-Banacloche J, Childs R et al, &quot;Hallucinations During Voriconazole Use,&quot; Abstract M-1172; 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September, 2007.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10118 Version 249.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F234784\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855140\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F234822\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F234787\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F234806\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F234788\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F234789\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F234790\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F48999062\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F234759\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F234745\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F234761\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133419\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F234760\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25497518\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F14694838\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234751\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F234764\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F234749\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F234816\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F234753\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F234780\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F234765\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F234766\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F234757\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F23620970\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F234748\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F234763\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324109\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F234768\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10118|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=voriconazole-patient-drug-information\" class=\"drug drug_patient\">Voriconazole: Patient drug information</a></li><li><a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Voriconazole: Pediatric drug information</a></li></ul></div></div>","javascript":null}